REDWOOD CITY, Calif., and HONG KONG, March 17, 2016 — Oncologists in Hong Kong and Macau can now order Guardant Health’s groundbreaking Guardant360 liquid biopsy for patients with advanced solid tumors, the companies announced. The partnership between Guardant Health and Sanomics expands Guardant Health’s distribution outside the United States, where nearly 2,000 oncologists are ordering 20,000 tests a year.
Guardant360 is the first commercially available comprehensive liquid biopsy. It detects and analyzes DNA fragments from solid tumors that circulate in the blood of patients with advanced cancers. It is used in the United States by oncologists to match patients with targeted therapies, while avoiding the costs and risks of a tissue biopsy.
“Because of the rise of targeted therapies, doctors and patients need access to genomic information to make the proper treatment decisions. But invasive tissue biopsies can be expensive, risky, and do not always produce the best results,” said Tony Yung, chief executive officer of Sanomics. “This agreement puts a useful tool in the hands of more local oncologists. It can contribute to better patient care and outcomes for patients fighting advanced cancer across the region.”
Sanomics will distribute Guardant360’s test package and handle local servicing. Guardant Health will perform all testing at its CLIA-certified, CAP-accredited facilities in Redwood City, Calif.
“Patients fighting advanced cancer should not have to subject themselves to potentially risky procedures to get the best information about their cancer,” said Helmy Eltoukhy, Guardant Health CEO. “Our test is already providing great benefits to patients in the United States. We are thrilled that physicians and patients in Hong Kong and Macau now have access to Guardant360.”
Guardant360 is the first CLIA-certified, CAP-accredited comprehensive next generation sequencing-based liquid biopsy. The 70-gene blood test is used in advanced cancer patients with visceral solid tumor cancers or metastases, and interrogates all four types of genomic alterations. The test is used to prevent repeat invasive biopsies when cancer has progressed or recurred despite treatment, or when an initial biopsy is unobtainable or has insufficient tissue. It is the only ctDNA test that includes all guideline-recommended somatic genomic targets in a single test. Unlike hotspot tests, Guardant360 sequences each covered exon completely to avoid missing rare mutations. Based on the tumor genomic profile, clinicians receive a report of actionable genomic alterations and a list of FDA-approved treatments and clinical trials for which the patient could be eligible. Guardant360 has undergone extensive analytical and clinical validation and is supported by publications with leading cancer centers globally.
About Guardant Health
Guardant Health is focused on developing breakthrough diagnostic technologies that can transform cancer from a silent killer into a manageable disease. Guardant Health was founded in 2012 by a team of serial entrepreneurs with expertise in next-generation sequencing, single-cell genomics and cancer diagnostics. The team is committed to improving patient health through technology that addresses long-standing unmet needs in oncology.
Sanomics is one of the leaders in cancer genomics services in Hong Kong and the Asia Pacific region. Its international operation spans across Hong Kong, China and other Asian countries. The Sanomics team is dedicated to bringing the latest and best genomics technologies to the local healthcare sectors, and helping oncologists manage patients with high-quality services.